<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370148</url>
  </required_header>
  <id_info>
    <org_study_id>087-CL-099</org_study_id>
    <nct_id>NCT01370148</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan</brief_title>
  <official_title>A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics and safety of a 48-hour&#xD;
      continuous infusion of conivaptan in subjects with severe liver impairment compared to&#xD;
      subjects with normal liver function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be admitted to the Phase 1 unit Day -2 and will remain confined to the unit&#xD;
      until discharge on Study Day 5 after completion of all study procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effect of severe hepatic impairment on the plasma drug concentration of conivaptan through analysis of blood samples</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>Subjects with severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with normal hepatic function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conivaptan hydrochloride</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Subjects with normal hepatic function</arm_group_label>
    <arm_group_label>Subjects with severe hepatic impairment</arm_group_label>
    <other_name>Vaprisol</other_name>
    <other_name>YM087</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects with Normal Hepatic Function:&#xD;
&#xD;
        Female subject must be either:&#xD;
&#xD;
          -  post-menopausal prior to Screening, or&#xD;
&#xD;
          -  premenarchal prior to Screening, or&#xD;
&#xD;
          -  documented surgically sterile or post hysterectomy, or&#xD;
&#xD;
          -  if of childbearing potential, must have a negative pregnancy test at Screening and&#xD;
             must be using highly effective contraception prior to Screening and throughout the&#xD;
             study period and for 28 days after final study drug administration&#xD;
&#xD;
               -  Female subject must not be lactating and must not be breastfeeding at Screening&#xD;
                  or during the study period, and for 28 days after final study drug administration&#xD;
&#xD;
               -  Female subject must not donate ova starting at Screening or during the study&#xD;
                  period, and for 28 days after final study drug administration&#xD;
&#xD;
               -  Male subject must:&#xD;
&#xD;
          -  be using highly effective contraception consisting of two forms of birth control (one&#xD;
             of which must be a barrier method) starting at Screening and continue throughout the&#xD;
             study period, and for 28 days after final study drug administration&#xD;
&#xD;
          -  not donate sperm starting at Screening and throughout the study period, and for at&#xD;
             least 28 days after final study drug administration&#xD;
&#xD;
               -  Subject weighs at least 45 kg and has a body mass index between 18 and 40 kg/m2&#xD;
                  inclusive&#xD;
&#xD;
               -  The subject must have clinical laboratory test results within normal range,&#xD;
                  including liver function tests (LFTs)&#xD;
&#xD;
               -  The subject must have had a normal 12-lead electrocardiogram (ECG)&#xD;
&#xD;
        Hepatic Impaired Subjects:&#xD;
&#xD;
          -  Female subject must be either:&#xD;
&#xD;
               -  post-menopausal prior to Screening, or&#xD;
&#xD;
               -  premenarchal prior to Screening, or&#xD;
&#xD;
               -  documented surgically sterile or post hysterectomy, or&#xD;
&#xD;
               -  if of childbearing potential, must have a negative pregnancy test at Screening&#xD;
                  and must be using highly effective contraception prior to Screening and&#xD;
                  throughout the study period and for 28 days after final study drug administration&#xD;
&#xD;
          -  Female subject must not be lactating and must not be breastfeeding at Screening or&#xD;
             during the study period, and for 28 days after final study drug administration&#xD;
&#xD;
          -  Female subject must not donate ova starting at Screening or during the study period,&#xD;
             and for 28 days after final study drug administration&#xD;
&#xD;
          -  Male subject must:&#xD;
&#xD;
               -  be using highly effective contraception consisting of two forms of birth control&#xD;
                  (one of which must be a barrier method) starting at Screening and continue&#xD;
                  throughout the study period, and for 28 days after final study drug&#xD;
                  administration&#xD;
&#xD;
               -  not donate sperm starting at Screening and throughout the study period, and for&#xD;
                  at least 28 days after final study drug administration&#xD;
&#xD;
          -  Subject meets criteria for severe hepatic impairment defined by Child-Pugh method&#xD;
&#xD;
          -  Subject weighs at least 45 kg and has a body mass index between 18 and 40 kg/m2&#xD;
             inclusive&#xD;
&#xD;
          -  The subject must have clinical laboratory test results within therapeutic range except&#xD;
             for hepatic disease&#xD;
&#xD;
          -  The subject must have had a normal 12-lead electrocardiogram (ECG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with Normal Hepatic Function:&#xD;
&#xD;
          -  Subject has a history of a clinically significant illness, and associated clinical&#xD;
             symptoms, medical condition, or laboratory abnormality within past 3 months that would&#xD;
             preclude participation in the study&#xD;
&#xD;
          -  Subject has evidence of biliary obstruction or other causes of hepatic impairment&#xD;
&#xD;
          -  Subject is known to have hepatitis or is a carrier of hepatitis B surface antigen&#xD;
             (HBsAg), hepatitis C virus (HCV) antibody, or is known to be HIV positive or has HIV&#xD;
             antibodies&#xD;
&#xD;
          -  Subject has an impaired ability to sense thirst&#xD;
&#xD;
          -  Subject has serum sodium less than 115mEg/L or greater than 140 mEg/L&#xD;
&#xD;
          -  Subject has either a systolic blood pressure (BP) of greater than 140 mmHg or a&#xD;
             diastolic BP of less than 56 mmHg&#xD;
&#xD;
          -  Subject has taken any prescription or over-the-counter medications except for&#xD;
             contraceptives, hormone replacement therapy and occasional acetaminophen, or&#xD;
             alternative and complementary medicines within past 14 days&#xD;
&#xD;
          -  Subject has a history of carcinoma, except for basal cell or cutaneous squamous cell&#xD;
             carcinoma within past 5 years&#xD;
&#xD;
          -  Subject drinks greater than 14 units of alcohol per week (Note: one unit = 12 ounces&#xD;
             of beer, 4 ounces of wine, or 1 ounce of spirits)&#xD;
&#xD;
          -  Subject has a history of substance abuse within past 6 months prior to Screening Visit&#xD;
             or the subject tests positive at Screening or clinic admission for alcohol or drugs of&#xD;
             abuse&#xD;
&#xD;
          -  Subject is currently participating in another clinical trial or has received an&#xD;
             investigational medication within past 30 days&#xD;
&#xD;
          -  Subject is known to have hypersensitivity to conivaptan or its derivatives&#xD;
&#xD;
          -  Subject has had a blood transfusion or donated/lost more than 550ml of blood within&#xD;
             past 8 weeks&#xD;
&#xD;
          -  Subject is incapable of being compliant with the protocol&#xD;
&#xD;
        Subjects with Hepatic Impairment:&#xD;
&#xD;
          -  Subject has a history of a clinically significant illness, and associated clinical&#xD;
             symptoms, medical condition, or laboratory abnormality within past 3 months that would&#xD;
             preclude participation in the study. Subjects with controlled hypertension may be&#xD;
             allowed&#xD;
&#xD;
          -  Subject has a condition associated with hepatic disease including; biliary&#xD;
             obstruction, or other cause of hepatic impairment not related to parenchymal disorder&#xD;
             and/or disease of the liver, fluctuating or rapidly deteriorating hepatic function,&#xD;
             biliary liver cirrhosis, history or presence of hepatic encephalopathy greater than&#xD;
             Grade 1 within past 3 months or unstable encephalopathy prior to Screening, tense&#xD;
             ascites, esophageal/gastric variceal bleeding with past 6 months, server portal&#xD;
             hypertension, surgical portal systemic shunt or peritoneal venous shunt, thrombocyte&#xD;
             level below 50,000 x 10^9/L and prothrombin time (PT) above 18 seconds&#xD;
&#xD;
          -  Subject is hypovolemic or has evidence of orthostatic hypotension&#xD;
&#xD;
          -  Subject has an impaired ability to sense thirst&#xD;
&#xD;
          -  Subject has serum sodium less than 115mEg/L or greater than 140 mEg/L&#xD;
&#xD;
          -  Subject has either a systolic blood pressure (BP) of greater than 140 mmHg or a&#xD;
             diastolic BP of less than 56 mmHg&#xD;
&#xD;
          -  Subject is known to be HIV positive or has HIV antibodies&#xD;
&#xD;
          -  Subject has had a change in dose regimen of medication needed for their underlying&#xD;
             medical condition with the past four weeks&#xD;
&#xD;
          -  Subject is currently taking a prohibited medication&#xD;
&#xD;
          -  Subject drinks greater than 14 units of alcohol per week (Note: one unit equals 12&#xD;
             ounces of beer, 4 ounces of wine, or 1 ounce of spirits)&#xD;
&#xD;
          -  Subject has a history of substance abuse within past 6 months prior to Screening Visit&#xD;
             or the subject tests positive at Screening or clinic admission for alcohol or drugs of&#xD;
             abuse&#xD;
&#xD;
          -  Subject is currently participating in another clinical trial or has received an&#xD;
             investigational medication with past 30 days&#xD;
&#xD;
          -  Subject has had a blood transfusion or donated/lost more than 550ml of blood within&#xD;
             past 8 weeks&#xD;
&#xD;
          -  Subject is known to have hypersensitivity of conivaptan or its derivatives&#xD;
&#xD;
          -  Subject is incapable of being compliant with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Art Wheeler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cumberland Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Protein Binding</keyword>
  <keyword>Conivaptan</keyword>
  <keyword>Vaprisol</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>YM087</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conivaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

